Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials - Eugenia-Toledo-Romaní, María; Verdecia-Sánchez, Leslyhana; Rodríguez-González, Meiby; Rodríguez-Noda, Laura; Valenzuela-Silva, Carmen; Paredes-Moreno, Beatriz; Sánchez-Ramírez, Belinda; Pérez-Nicado, Rocmira; González-Mugica, Raul; Hernández-García, Tays; Bergado-Baez, Gretchen; Pi-Estopiñán, Franciscary; et al. (Vaccine, 2022)
Keywords: Adult; Aged; Aged, 80 and over; Allergy and Immunology; Antibodies; Antibodies, Neutralizing; Antibodies, Viral; Antigens; blood serum; Clinical medicine; Clinical trials; Conjugate vaccine; Coronaviruses; COVID-19; COVID-19 - prevention & control; COVID-19 - therapy; COVID-19 infection; COVID-19 Serotherapy; COVID-19 vaccines; COVID-19 Vaccines - adverse effects; Enzyme-linked immunosorbent assay; Heterologous immunization scheme; Homology; Humans; Immune response; Immune system; Immunization, Passive; Immunogenicity; Immunogenicity, Vaccine; Immunoglobulin G; Immunology; Laboratory animals; Lymphocytes T; Middle Aged; Neutralization; pain; Proteins; Safety; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Subunit vaccine; T-lymphocytes; Tetanus; Vaccines; Young Adult; Cuba; COVID-19; SARS-CoV-2; Heterologous immunization scheme; Conjugate vaccine; Subunit vaccine